References
- Center for Disease Control [Internet]. National diabetes statistics report 2017; 2018 Jun [cited 2019 Oct 19]. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
- Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123(3):S3–S11.
- de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–2539.
- Hippisley-Cox J, Coupland C. Predicting the risk of chronic Kidney Disease in men and women in England and Wales: prospective derivation and external validation of the QKidney scores. BMC Fam Pract. 2010;11(1):49.
- Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1(1):15018.
- Wang V, Vilme H, Maciejewski ML, et al. The economic burden of chronic kidney disease and end-stage renal disease. Semin Nephrol. 2016;36(4):319–330.
- Vekeman F, Yameogo ND, Lefebvre P, et al. Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients. J Med Econ. 2010;13(4):673–680.
- National Committee for Quality Assurance. HEDIS® & performance measurement [Internet]; 2017 Nov [cited 2019 Oct 19]. Available from: http://www.ncqa.org/hedis-quality-measurement
- National Committee for Quality Assurance [Internet]. Hospitalization for potentially preventable complications: rate of discharges for ambulatory care sensitive conditions (ACSC) per 1,000 members and the risk-adjusted ratio of observed to expected discharges for ACSC by chronic and acute conditions, for members 67 years of age and older 2015; 2017 Dec [cited 2019 Oct 19]. Available from: https://www.qualitymeasures.ahrq.gov/summaries/summary/49840/hospitalization-for-potentially-preventable-complications-rate-of-discharges-for-ambulatory-care-sensitive-conditions-acsc-per-1000-members-and-the-riskadjusted-ratio-of-observed-to-expected-discharges-for-acsc-by-chronic-and-acute-conditions-for-members-67-ye
- National Committee for Quality Assurance. NCQA release new standards category – population health management [Internet]; 2018 Mar [cited 2019 Oct 19]. Available from: https://www.ncqa.org/newsroom/details/ncqa-releases-new-standards-category-population-health-management?ArtMID=11280&ArticleID=88&tabid=2659
- Lin CC, Li CI, Liu CS, et al. Development and validation of a risk prediction model for end-stage renal disease in patients with type 2 diabetes. Sci Rep. 2017;7(1):10177.
- Wan EYF, Fong DYT, Fung CSC, et al. Prediction of new onset of end stage renal disease in Chinese patients with type 2 diabetes mellitus – a population-based retrospective cohort study. BMC Nephrol. 2017;18(1):257.
- Herget-Rosenthal S, Dehnen D, Kribben A, et al. Progressive chronic kidney disease in primary care: modifiable risk factors and predictive model. Prev Med. 2013;57(4):357–362.
- Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553–1559.
- Elley CR, Robinson T, Moyes SA, et al. Derivation and validation of a renal risk score for people with type 2 diabetes. Diabetes Care. 2013;36(10):3113–3120.
- Dunkler D, Gao P, Lee SF, et al. Risk prediction for early CKD in type 2 diabetes. CJASN. 2015;10(8):1371–1379.
- Jardine MJ, Hata J, Woodward M, et al. Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis. 2012;60(5):770–778.
- Xie Y, Maziarz M, Tuot DS, et al. Risk prediction to inform surveillance of chronic kidney disease in the US Healthcare Safety Net: a cohort study. BMC Nephrol. 2016;17(1):57.
- KDIGO [Internet]. Clinical practice guideline for the evaluation and management of chronic kidney disease 2013; 2017 Dec [cited Oct 19]. Available from: http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf
- Young JB, Gauthier-Loiselle M, Bailey RA, et al. Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. Cardiovasc Diabetol. 2018;17(1);118.
- National Institute of Health. estimated glomerular filtration rate in evaluating patients with diabetes for kidney disease. National Kidney Disease Education Program. Publication No. 10-6286. 2010.
- Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
- Chang HY, Weiner JP, Richards TM, et al. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Managed Care. 2012;18(11):721–726.
- Akaike H. A new look at the statistical model identification. Selected papers of Hirotugu Akaike. New York (NY): Springer; 1998;215–222.
- Bang H, Vupputuri S, Shoham DA, et al. SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med. 2007;167(4):374–381.
- Chien KL, Lin HJ, Lee BC, et al. A prediction model for the risk of incident chronic kidney disease. Am J Med. 2010;123(9):836–846.e2.
- Halbesma N, Jansen DF, Heymans MW, et al. Development and validation of a general population renal risk score. CJASN. 2011;6(7):1731–1738.
- Kshirsagar AV, Bang H, Bomback AS, et al. A simple algorithm to predict incident kidney disease. Arch Intern Med. 2008;168(22):2466–2473.
- Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003;63(1):225–232.
- Hallan SI, Dahl K, Oien CM, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006;333(7577):1047.
- Sheen YJ, Lin JL, Li TC, et al. Peripheral arterial stiffness is independently associated with a rapid decline in estimated glomerular filtration rate in patients with type 2 diabetes. Biomed Res Int. 2013;2013:1–10.
- Sheen YJ, Sheu WH. Risks of rapid decline renal function in patients with type 2 diabetes. WJD. 2014;155(6):835–846.
- Luo Y, Li X, Li J, et al. Peripheral arterial disease, chronic kidney disease, and mortality: the Chinese ankle brachial index cohort study. Vasc Med. 2010;15(2):107–112.
- American Diabetes Association. Standards of medical care in diabetes-2017: summary of revisions. Diabetes Care. 2017;40(Suppl 1):S4–S5.
- Strippoli GF, Craig M, Schena FP, et al. Antihypertensive agents for primary prevention of diabetic nephropathy. JASN. 2005;16(10):3081–3091.
- Yu MK, Kim SH. Second-Line agents for the treatment of type 2 diabetes and prevention of CKD. CJASN. 2016;11(12):2104–2106.
- Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
- Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5(9):709–717.
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
- Barutta F, Bernardi S, Gargiulo G, et al. SGLT2 inhibition to address the unmet needs in diabetic nephropathy. Diabetes Metab Res Rev. 2019;35(7):e3171.
- Newman JD, Berger JS, Ladapo JA. Underuse of medications and lifestyle counseling to prevent cardiovascular disease in patients with diabetes. Diabetes Care.. 2019;42(5):e75–e76.
- Boye KS, Botros FT, Haupt A, et al. Glucagon-like peptide-1 receptor agonist use and renal impairment: a retrospective analysis of an electronic health records database in the U.S. Population. Diabetes Ther. 2018;9(2):637–650.
- Taal MW. Predicting renal risk in the general population: do we have the right formula?. CJASN. 2011;6(7):1523–1525.
- Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290(23):3101–3114.
- Porter ME. A strategy for health care reform – toward a value-based system. N Engl J Med. 2009;361(2):109–112.